April 30, 2019
WELLESLEY, Mass., April 30, 2019–Global interest in ubiquitin proteasome systems is growing as researchers find new fields of research to pursue and probe unexplored strategies, according to a report by BCC Research.
Targeted protein degradation, in particular, is renewing optimism in what was once a field full of “garbage proteins,” according to the report “Nothing Degrading about Saving Lives: E3 Ligands Recruiting New Drugs.”
“Although it is obviously exciting that E3 ligases are revived as a drug target in drug discovery, more importantly it brings a possibility to develop drugs against very challenging proteins,” notes report author Marianna Tcherpakov. “One very ‘difficult’ target is tau protein related to Alzheimer’s. Solubilizing or degrading protein plaques is not a trivial mission, therefore systems like PROTAC represent an opportunity to overcome disadvantages of previous technologies.”
Work by Arvinas to Create a New Class of Drugs
Arvinas is developing a new class of drugs that engages the body’s own natural protein disposal system to treat cancers and other difficult diseases. As a potential improvement over traditional small molecule inhibitors, proteolysis-targeting chimera protein degraders are able to degrade disease-causing proteins through the cell’s ubiquitin proteasome system, which routinely degrades proteins. This is just one example of companies using targeted protein degradation platforms in drug discovery.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at email@example.com.
Nothing Degrading about Saving Lives: E3 Ligands Recruiting New Drugs( PHM192A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.